Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22388850 | 0.75 | ESR1 (0.43) | ESR1ESR2APLNRKCNH2HRH1 | |
| SCHEMBL21076444 | 0.74 | ESR1 (0.42) | ESR1ESR2APLNRKCNH2HRH1 | |
| SCHEMBL12120606 | 0.72 | — | — | |
| SCHEMBL469177 | 0.69 | APLNR (0.46) | ESR1ESR2APLNRKCNH2HRH1 | |
| SCHEMBL18596819 | 0.69 | APLNR (0.46) | ESR1ESR2APLNRKCNH2HRH1 | |
| SCHEMBL10116217 | 0.69 | APLNR (0.46) | ESR1ESR2APLNRKCNH2HRH1 | |
| SCHEMBL14472465 | 0.69 | APLNR (0.46) | ESR1ESR2APLNRKCNH2HRH1 | |
| SCHEMBL179299 | 0.68 | APLNR (0.51) | ESR1ESR2APLNRKCNH2HRH1 | |
| SCHEMBL13365274 | 0.68 | APLNR (0.49) | ESR1ESR2APLNRKCNH2HRH1 | |
| SCHEMBL19492398 | 0.68 | ESR1 (0.38) | ESR1ESR2APLNRKCNH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | INTEGRAL BIOSCIENCES PRIVATE LTD (IN) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ACVR1, ACVRL1, ALK | ESR1 2391/4885ESR2 385/4885APLNR 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.